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Helicobacter pylori is a helical- or spiral-shaped, micro-
aerophilic, Gram-negative bacterium that colonizes the
apical side of human gastric epithelial cells and mucous
layers [1]. The discovery and successful culture of H. pyl-
ori by Marshall and Warren in 1982 revolutionized the
diagnosis and treatment of gastroduodenal disease [2].
This organism has been categorized as a class I carcino-
gen by the World Health Organization [3,4] and direct
evidence of carcinogenesis was recently demonstrated in
an animal model. H. pylori infection is associated with
peptic ulcer diseases such as gastric or duodenal ulcer,
atrophic gastritis, gastric cancer, and mucosa-associated
lymphoid tissue lymphoma [2,5]. Hence, the identification
and prevention and/or treatment of H. pylori infection can
prevent considerable mortality resulting from chronic in-
fection. During the process of H. pylori infection, the anti-
gens secreted from the bacterium elicit strong antibody
responses in the host; thus, secreted H. pylori antigens
may be studied as potential infection biomarkers [6]. Vari-
ous H. pylori proteins had been employed as infection
markers for diagnosis, such as CagA, VacA, HspB, FlaA,
FlaB, and UreC [7,8].
On initial infection of gastric cells, the host responds
strongly to the presence of H. pylori through both the in-
nate and acquired immune systems. Antigen-presenting B
cells differentiate into plasma cells, which produce anti-
bodies such as IgA, IgG, and IgM as the second line of
defense, with IgA as the first antibody secreted [9,10].
During the early stages of H. pylori infection, IgM anti-
bodies are secreted by plasma cells before there is a suffi-
cient titer of IgG in the blood [6]. Human studies have
shown that the presence of anti-H. pylori IgA in maternal
milk is associated with delayed colonization in infants,
suggesting that IgA can block infection. In another study
by Argent and Atherton (2007), IgG antibodies proved to
be a useful tool for the serodiagnosis of H. pylori infection
[11]. In summary, these studies suggested that anti-H. pyl-
ori antibodies can be used for diagnosis, to reduce infec-
tion and, by inference, could be an effector mechanism in
prophylactic vaccination as well. During H. pylori infec-
tion, antibodies of the classes IgG and IgA can be de-
tected, while IgM antibodies have been found to have little
diagnostic utility. This may be explained by the fact that
H. pylori infection is a chronic condition and IgM anti-
body is secreted in the acute phase of infection [12].
One approach to identify antigen candidates for diag-
nostic purposes is to isolate the bacterium from the bi-
opsy samples of patients and use the antisera from the
patients to screen for reactive proteins in western blot
analysis. This would then be followed by purification of
the immunoreactive proteins, determination of the amino
acid sequence, nucleotide sequence elucidation, cloning,
and recombinant protein expression [13].Using a similar approach, Khalilpour et al. (2013)
studied a local (Malaysian) H. pylori isolate to identify
potential diagnostic markers. Four protein bands were
identified by western blot analysis using IgG from serum
samples of culture-positive patients and control sera
[14]. Out of the four proteins identified (UreG, UreB,
CagI, and pyrroline-5-carboxylate dehydrogenase), UreG
was selected for further work because it is a novel pro-
tein in terms of potential utility for diagnosis. It is also
an interesting protein because it is frequently required
to complete the biosynthesis of nickel enzymes [15]. In
the present study, the UreG protein was investigated fur-
ther. We report the cloning and expression of the UreG
coding sequence and determination of its seroreactivity.Methods
Ethical approval
Written informed consent from the patient was obtained
for use of his duodenal biopsy sample in this study. In
addition written informed consents were obtained from
each patient prior to collection of their serum samples. Ap-
proval for this study was obtained from the Universiti Sains
Malaysia Human Research Ethics Committee (Ref no:
USMKK/PPP/JEPeM [214.3.4]). This approval included the
collection and use of the H. pylori strain isolated from the
human duodenal biopsy sample, the collection and use of
serum samples and the use of stored control serum sam-
ples. The use of mice in this study was approved by Uni-
versiti Sains Malaysia Animal Research Ethics Committee
[Ref. no: USM/Animal Ethics Approval/2012 (75) (407)].Bacterial culture and extraction of genomic DNA
The H. pylori strain used in this study (HpUSM3121108)
was isolated from a human duodenal biopsy sample ob-
tained from a patient with a duodenal ulcer at the Sebar-
ang Jaya Hospital, Penang, Malaysia. H. pylori was
cultured on tryptic soy blood agar with 5% defibrinated
sheep blood under microaerophilic conditions (10%
CO2, 5% oxygen, 85% nitrogen in air) at 37°C for 5–
7 days [16,17]. The bacterial cells were aseptically har-
vested by adding 3 mL phosphate-buffered saline (PBS,
pH 7.2) to the agar plate; the bacterial suspension from
the plate was then collected and placed in a 10-mL cen-
trifuge tube, and centrifuged at 3000 × g at 4°C for
15 min. The pellet was washed by resuspending in 1 mL
of PBS, transferred into a 1.5-mL microcentrifuge tube,
followed by centrifugation at 11,000 × g. The washing step
was repeated twice, then the final fresh bacterial cell pellet
was used for genomic DNA extraction using the Bacterial
Genomic DNA Extraction Kit (DNeasy; Qiagen, Hilden,
Germany). The DNA was suspended in TE buffer and
stored at −20°C [18,19].
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The sequence of the ureG gene was deposited in the Gen-
Bank database with accession number KC576840 [20].
The ureG gene was amplified by polymerase chain reac-
tion (PCR) using a forward primer containing a HindIII
restriction site and a reverse primer containing an EcoRI
site: 5′-AAG CTT TCA ATC TTC CAA TAA AGC GTT
G-3′ and 5′-GAA TTC ATG GTA AAA ATT GGA GTT
TGT GG-3′. PCR was performed in an automatic thermal
cycler using a 50-μL reaction mixture containing 7 μL of
10× PCR buffer, 3 μL of sample DNA, 1 μL of 10 mmol/L
dNTPs, 2 μL of 20 pmol/L primers, and 2.5 U of Taq poly-
merase. The mixture was incubated for 2 min at 94°C for
initial denaturation of the target DNA, then 35 cycles of
denaturation at 94°C for 1 min, annealing at 53.8°C for
1 min, and elongation at 72°C for 2 min. The amplified
products (5 μL) were analyzed by agarose electrophoresis
and then visualized under ultraviolet light.
Recombinant plasmid construction and purification
The PCR product was purified using the PCR Fragment
Recovery Kit (Promega, Madison, WI, USA). In prepar-
ation for cloning, an A-tailing reaction was performed.
The reaction mixture comprised 10 μL of purified PCR
product, 1 μL of 10× PCR buffer (with MgCl2), 1 μL of
12.5 mmol/L of dATP, and 3.75 U of Taq polymerase.
After incubation at 72°C for 30 min, the A-tailed PCR
product was cloned in the pCR®2.1-TOPO vector sup-
plied in the TOPO™-TA Cloning Kit (Invitrogen, Carlsbad,
CA, USA). The reaction contained 4 μL of purified PCR
product, 1 μL of salt solution, 1 μL of pCR®2.1-TOPO vec-
tor, and 1 μL of water (Bioline, USA). The reaction mix-
ture was then transformed into TOP10F Escherichia coli
and positive clones were selected on agar containing X-gal
and identified by PCR and restriction enzyme digestion. A
single positive bacterial colony was cultivated in 3 mL of
LB broth containing 100 mg/L of ampicillin, with shaking
(300 rpm), at 37°C overnight. Recombinant plasmids
(TOPO®/ureG) were extracted using the DNA Purification
Kit (Promega) and checked by PCR and restriction endo-
nuclease digestion.
For sub-cloning into the pRSET vector (Invitrogen),
endonuclease digestion was performed on the TOPO®/
ureG recombinant plasmids and pRSET version “a” (Invi-
trogen) to generate fragments with EcoRI and HindIII di-
gestion sites. Then, a ligation reaction was prepared,
which consisted of 17 μL of gel-purified insert, 1 μL of
pRSET vector, 2 μL of DNA dilution buffer, and 10 μL of
rapid ligation buffer. The reaction was started by adding 5
U of T4 DNA ligase, the mixture was mixed by pipetting
and then incubated at 15–25°C for 5 min. The circular re-
combinant plasmid was then transformed into a competent
expression host [E. coli BL21 (DE3) pLysS] (Invitrogen) and
plated onto LB agar which contained 100 μg/mL ofampicillin and 35 μg/mL of chloramphenicol. DNA sequen-
cing of the cloned and sub-cloned ureG gene of the recom-
binant plasmid was performed by the Centre for Chemical
Biology (CCB) at Universiti Sains Malaysia. The nucleo-
tide and amino acid sequences were then analyzed using
the BioEdit software (Ibis Biosciences, Carlsbad, USA)
and compared with published sequences in the public
databases.
Expression of recombinant protein
A pre-culture was first established by inoculating a sin-
gle colony of the recombinant bacteria from a freshly
subcultured LB plate (containing 100 μg/mL of ampicil-
lin and 35 μg/mL of chloramphenicol) into 100 mL of
Terrific broth (TB) containing the same antibiotics as
above, followed by overnight incubation at 37°C, with
shaking (180 rpm). The TB was prepared by dissolving
12 g bacto-tryptone, 24 g yeast extract, and 4 mL gly-
cerol in 900 ml deionized water, then autoclaving. The
TB was then made up to 1 L with salt solution prior to
use. The salt solution was prepared by dissolving 125.4 g
dipotassium hydrogen phosphate (K2HPo4) and 23.1 g
potassium dihydrogen phosphate (KH2PO4) in 1 L de-
ionized water, then autoclaving.
For large-scale expression, 4 L (eight 500-mL cultures
in 1-L flasks) of fresh TB were used. Each flask was inoc-
ulated with 25 mL of the above pre-culture and incu-
bated at 37°C, with shaking (200 rpm) until the OD600
reached 0.5. The recombinant bacteria were induced to
express recombinant UreG (rUreG) by the addition of
1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG;
Fermentas, Hanover, MD, USA), followed by incubation
at 37°C, with shaking (200 rpm), for 4.5 h. The cells were
then harvested by centrifugation at 10,000 × g at 4°C for
10 min. The cell pellet was resuspended in 10 mL of lysis
buffer (containing 10 mM imidazole and 0.1% Triton-X
100), lysozyme (0.5 mg/mL; Amresco, Solon, OH, USA),
and a cocktail of protease inhibitors (14.8 μg/mL; Roche
Applied Science, Indianapolis, IN, USA), incubated on ice
for 30 min, followed by lysis using a French press 40 K
(Thermo Spectronic, Rochester, NY, USA). The super-
natant (containing soluble protein) and the pellet (contain-
ing inclusion bodies) were separated by centrifugation at
10,000 × g at 4°C for 10 min, and both components were
retained for subsequent procedures.
Purification of rUreG under native conditions
DNaseI was added (5 μg/mL) to the supernatant (pre-
pared as above), incubated on ice for 10–15 min, centri-
fuged at 10,000 × g at 4°C for 30 min, and then syringe
filtered (0.45 μm). Finally, the supernatant was incubated
with 1 mL of washed nickel nitrilotriacetic acid (Ni-
NTA) resin (Qiagen) packed in a column for 1 h at 4°C.
To maximize the purity of the recombinant protein, the
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gradient of increasing imidazole concentrations. This
comprised four buffers, each containing the basic buffer
(50 mM NaH2PO4, 300 mM NaCl) with the addition of
imidazole concentrations of 10–20 mM, 30 mM, and
40 mM. Each washing step was performed with 10 col-
umn volumes of buffer. Finally, the purified recombinant
protein was eluted with 10 column volumes of elution
buffer (50 mM NaH2PO4, 300 mM NaCl, and 250 mM
imidazole); this buffer contained an excess of imidazole
to allow displacement of the His-tag from nickel co-
ordination, thus the His-tagged recombinant protein was
able to be eluted. The protein-containing fractions were
pooled and buffer exchanged into PBS containing 1 M
urea using a spin column with a 3-kDa molecular
weight cut-off (Vivapsin; Sartorius, USA), this was re-
peated three times. The protein concentration was de-
termined using a commercial protein assay kit (RC
DC™; BioRad, Hercules, CA, USA), and the protein was
stored at −80°C.
Purification of rUreG under denaturing conditions
The protein pellet, prepared as described above, was dis-
solved in 15 mL of denaturing lysis/binding buffer (7 M
urea, 100 mM NaH2PO4, 10 mM Tris-HCl, pH 8.0) and
incubated in a shaker for 15–30 min, then centrifuged at
10,000 × g at 4°C for 10 min. DNaseI was mixed with the
supernatant and incubated on ice for 30 min, then cen-
trifuged at 10,000 × g at 4°C for 30 min and syringe fil-
tered (0.45 μm). The supernatant was then incubated
with 1 mL of washed Ni-NTA resin (Qiagen) for 1 h at
4°C. The mixture was loaded into a purification column
pre-equilibrated with denaturing lysis buffer. The column
was washed twice with 10 mL of denaturing buffer (8 M
urea, 100 mM NaH2PO4, 10 mM Tris-HCl, pH 6.1). The
recombinant protein was eluted as 500-μL fractions with
10 mL of denaturing elution buffer D (8 M urea, 100 mM
NaH2PO4, 10 mM Tris-Cl, pH 5.9) and the protein con-
tent was confirmed using a protein assay kit (Bio-Rad).
More fractions were collected using elution buffer E (8 M
urea, 100 mM NaH2PO4, 10 mM Tris-Cl, pH 4.5) until no
more protein was observed. The purified fractions were
pooled and buffer-exchanged five times (as described
above) into storage buffer containing 50 mM Tris-HCl,
150 mM NaCl, and 5% glycerol. The protein concentra-
tion was determined using a commercial protein assay
(RC DC™, BioRad), and the protein was stored at −80°C.
Serum samples
The serum samples were first tested using a commercial
H. pylori IgG-ELISA kit (Adaltis, Bologna, Italy) and di-
vided into several categories on the basis of their sero-
logical profiles. Group I: serum samples from patients
whose biopsy cultures were positive for H. pylori andanti-H. pylori IgG antibodies (n = 30). This group com-
prised two patients with duodenal ulcers, five patients
with gastric ulcers, 20 patients with gastritis, and three
patients with normal scope findings. Group II: serum
samples from healthy individuals with no history of gas-
tric disorders (n = 10). Group III: serum samples from
patients with gastrointestinal complaints who were re-
ferred to the endoscopy unit; however, their tissue bi-
opsy cultures were negative for H. pylori (n = 20). Group
IV: serum samples from people with other diseases, such
as typhoid, leptospirosis, E. coli septicemia, shigellosis,
Staphylococcus aureus septicemia, and amoebic liver ab-
scess (n = 10). Sera from groups II–IV tested negative for
anti-H. pylori IgG antibodies and served as control sera.
Control sera were previously stored samples from the
serum bank at INFORMM (Universiti Sains Malaysia).
SDS-PAGE and western blot analysis
The recombinant protein preparations were each loaded
at 20 μg per well onto a 12% resolving gel, and SDS-
PAGE was performed at 100 V. The gel was transferred
onto a nitrocellulose membrane (0.45 μm; BioRad) using a
semi-dry transblot (BioRad), then blocked with 5% alkali-
soluble casein overnight at 4°C. The membrane was then
washed four times with Tris-buffered saline containing
0.05% Tween 20 (TBS-T; 50 mM Tris, 150 mM NaCl,
0.05% Tween-20). For the detection of histidine-tagged
protein, the membrane was incubated with anti-His-HRP
(Novagen, Germany) (1:1000) for 1 h at room temperature.
After a washing step, substrate development was per-
formed using enhanced chemiluminescence blotting re-
agent (Roche Diagnostics, Mannheim, Germany) and
Kodak films (Kodak, USA).
For western blotting using the serum samples, after
transfer of the recombinant protein onto the nitrocellu-
lose membrane, the membrane was washed four times
with TBS-T, then blocked with 1% blocking solution
(Roche Diagnostics) for 1 h at room temperature on a
shaker. After one more wash, the membrane was cut
into strips, then incubated at 4°C overnight with differ-
ent groups of serum samples as the primary antibody
(1:25 dilution in TBS). Following three washing steps,
the strips were incubated with monoclonal mouse anti-
human IgG-HRP (1:4000 in TBS; Invitrogen) or mono-
clonal mouse anti-human IgA-HRP (1:2000 in TBS) for
1 h, followed by washing with TBS-T. Substrate develop-
ment was performed as described above.
In-gel digestion of proteins and MS-MS analysis
The recombinant protein band was manually excised from
the Coomassie blue-stained gel and destained by incubat-
ing with 200 μL of destaining solution for 30 min at 37°C
with shaking. The gel slice was digested and extracted
using the Agilent Protein In-gel Trypsin Digestion Kit
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ZipTipC18 pipette tips (Zip-Tip U-C18; Millipore,
Bedford, MA, USA), eluted, and concentrated using a
vacuum concentrator (Eppendorf, Westbury, NY, USA)
until completely dry. The protein was then analyzed
using MALDI-TOF-TOF 4800 (ABSCIEX, Foster City,
CA, USA).
Production of hyperimmune mice serum against UreG
recombinant protein and antigenicity determination
Pre-immunized serum was obtained from four mice
(aged 4–6 weeks) by bleeding from the tail, then pooled
for use as control serum [21]. Next, a mixture contain-
ing 200 μL of Freund’s complete adjuvant (CFA) and
200 μL of 200 μg UreG recombinant antigen was sub-
cutaneously injected into each of the four mice. Two
booster injections were given at 2-week intervals, one
using Freund’s incomplete adjuvant (IFA) mixed with the
recombinant antigen and another using the recombinant
antigen alone. Blood from each mouse was centrifuged to
extract the serum sample. Then, serum samples from all
four mice were pooled for use as the primary antibody.
H. pylori lysate antigen and the purified UreG recom-
binant protein were electrophoresed at 20 μg per well
on a 12% SDS-PAGE, then transferred onto nitrocellu-
lose membrane as explained above. The membrane was
blocked, washed, cut into strips, and incubated with the
pooled mice serum, then probed with monoclonal hu-
man anti-mouse IgG-HRP (Invitrogen). The strips were
then washed four times with TBS-T and developed using
chemiluminescence substrate as described above.
Results
The presence and orientation of the DNA sequences of
the ureG gene in PCR2.1 TOPO and the pRSET con-
structs was confirmed by performing PCR with the vec-
tor and gene-specific primers and DNA sequencing.
Figure 1 shows amplification of the ureG gene from the
pRSET/ureG recombinant plasmid and excision of this
gene from the plasmid using enzymes HindIII and
EcoRI. DNA sequence analysis of the TOPO/ureG and
pRSET/ureG constructs confirmed that ureG was in the
correct reading frame (data not shown).
Figure 2 shows the results of western blot analysis of
the purified recombinant protein prepared from the
supernatant and pellet of the lysed cells to check for the
presence of the six-histidine fusion in the UreG recom-
binant protein; a thick distinctive band was observed at
the expected molecular weight of approximately 28 kDa.
MALDI TOF-TOF results confirmed the identity of the
protein as UreG; with scores of 454 with 10 matched
peptides and 462 with six matched peptides from bands
excised from SDS-PAGE of native and denatured forms
of the recombinant protein, respectively.Although western blot analysis indicated that the
expressed UreG target protein was present in both the
supernatant and pellet of the lysed cells, the amount of
protein in the pellet (insoluble protein) was 3 mg/L of
culture, compared with 1.4 mg/L of culture (soluble pro-
tein) in the supernatant.
The UreG recombinant protein showed 70% (21/30)
and 60% (18/30) reactivities with Group 1 sera (culture-
positive patients) when probed with anti-human IgG-
HRP and anti-human IgA-HRP respectively. When the
results of the IgG and IgA western blots were combined,
the positive reactivity rate was 83.3% (25/30). Among
the control sera (Groups II, III, and IV), 97.5% and
92.5% were not reactive when probed with anti-human
IgG-HRP and anti-human IgA-HRP, respectively.
Both the H. pylori lysate antigen and purified UreG
recombinant protein displayed a distinctive band at the
expected molecular weights of 25 kDa and 28 kDa re-
spectively when probed with hyperimmune mice serum
(Figure 3). This demonstrated that the polyclonal anti-
body against UreG recombinant protein was recognized
by both native and recombinant UreG proteins.
Discussion
Several virulence-associated genes have been identified
in H. pylori and these are believed to play a major role
in the pathogenesis of this organism. The proteins
expressed by some of these genes, such as UreB, VacA,
CagA, HspB, FlaA, FlaB, and outer membrane proteins,
have been investigated as diagnostic indicators of H. pyl-
ori infection [7,8,19,22].
The production of a wide range of proteins was previ-
ously unattainable because of the limitations imposed by
the use of native proteins. In recent times however, ad-
vances in recombinant technology have made it possible
to produce a wide range of defined antigens in large quan-
tities for use in diagnostic applications. For H. pylori, a
variety of recombinant protein antigens, such as rUreB,
rVacA, rCagA, rHpaA, rNapA, rFlaA, and rFlaB, have
been constructed, expressed, and purified by affinity chro-
matography. These recombinant antigens could improve
serodiagnosis of H. pylori infection, replacing the complex
native H. pylori antigens [23-25]. In one study, rUreB was
used as the antigen in ELISA to identify a specific antibody
in serum samples from H. pylori-infected patients. In
addition, the anti-rUreB rabbit polyclonal antibody was
used to study UreB expression in different H. pylori iso-
lates. A specific antibody against rUreB in the sera of
H. pylori-infected patients and high frequencies of UreB
expression in various H. pylori isolates indicated that
rUreB is a good antigen candidate for developing H. pylori
diagnostic tests and vaccines [26]. Furthermore, combina-
tions of purified rUreA/rUreB have been shown to induce
H. pylori-specific responses in human volunteers [27].
Figure 1 PCR amplification of the ureG gene and verification of the recombinant prokaryotic expression plasmid pRSET-ureG. A: PCR
amplification of the ureG gene B: PCR screening of the pRSET/ureG recombinant C: Digestion product of pRSET/ureG with HindIII and EcoRI M:
100 bp DNA ladder.
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its encoded protein is expressed as an accessory protein
required for nickel ion insertion into the apoenzyme of
urease [26,28]. In the biosynthesis process of the active
metal-bound form of urease (a nickel-dependent enzyme),Figure 2 Western blot analysis showing the immunogenicity and specific
native condition probed with monoclonal anti-histidine-HRP B: rUreG purified u
C: rUreG incubated with primary antibodies from different groups of serum sam
patient) 2: Primary antibody from the Group II serum sample (healthy person) 3
patients seronegative) 4: Primary antibody from the Group IV serum sample (paa lysine carbamate functional group is formed alongside the
delivery of two Ni (2+) ions into the precast active site of the
apoenzyme [15,29]. UreG plays the role of chaperone in the
urease active site assembly and is required to complete the
biosynthesis of the nickel enzyme [15]. However, prior toity of the purified UreG recombinant protein. A: rUreG purified under
nder denaturing condition probed with monoclonal anti-histidine-HRP
ples: 1: Primary antibody from the Group I serum sample (culture-positive
: Primary antibody from the Group III serum sample (culture-negative
tient with other disease) MW: low molecular weight marker.
Figure 3 Western IgG blot incubated with mice hyperimmune pooled serum. A: native H. pylori antigen B: rUreG antigen 1: Pooled serum
before 1st injection (control) 2: Pooled serum before 2nd injection 3: Pooled serum before 3rd injection 4: Pooled serum after 3rd injection MW:
low molecular weight marker.
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of its potential as a diagnostic marker of H. pylori infection.
In the present study, rUreG was produced as both a
soluble and insoluble protein, thus purification was per-
formed under both native and denaturing conditions;
however, the yield of the latter was almost twice that of
the former. On the IgG and IgA western blot analysis,
the reactivities of soluble rUreG were 70% and 60%, re-
spectively, with sera from culture-positive patients. A
combination of the IgG and IgA western blots gave a
higher rate of reactivity of 83.3% (25/30). In comparison,
in our previous study, the native UreG protein showed
73.3% (22/30) and 63.3% (19/30) reactivities when
probed with IgG and IgA, respectively; while a combin-
ation of the IgG and IgA western blots showed 87% re-
activity [14]. Thus, the diagnostic sensitivities of the
native and recombinant forms of the UreG protein were
similar. The specificity of the rUreG was found to be
97.5% and 92.5% when probed with anti-human IgG-
HRP and anti-human IgA-HRP, respectively. In compari-
son, native UreG showed 100% specificity [14]. The reason
for the higher specificity of native UreG compared with
rUreG is not known. Mapping the epitope of the recom-
binant protein or the use of a peptide-based assay may
lead to increased specificity of the recombinant protein.
Studies with urease showed that it yielded protection
in only about 80% of immunized mice [30]. In a Helico-
bacter felis model, oral immunization in mice was per-
formed with a combination of recombinant H. pylori
heat-shock protein A (HspA) and urease; this dual antigen
immunization induced 100% protection against H. pylori
infection [31,32]. This indicated that the combination ofmultiple antigens can be effective in the development of a
good protective vaccine against H. pylori infection [30,31].
Similarly, in another study, immunization with rHpaA or
rUreB alone was found to induce weak immune responses;
however, when both antigens were pooled, together with
cholera toxin, strong immune responses were produced
that induced protection against H. pylori infection [32,33].
Because, in this study, rUreG has been shown to be im-
munogenic in mice, it should also be investigated for its
potential as a vaccine candidate.
Similar to the multiple antigen concept mentioned
above, in some commercial diagnostic kits, a mixture of
antigens is used because it provides higher sensitivity
and specificity compared with using a single antigen
[17,34-37]. This approach is further justified by reported
findings that the sensitivity of some diagnostic kits varied
depending on geographical location, with possible reasons
being H. pylori strain heterogeneity, cross-reactivity with
other intestinal pathogens, and varying immunological re-
sponses to H. pylori antigens in different patient popula-
tions [38-40]. In this study, although rUreG showed good
seroreactivity to H. pylori patients’ sera, it did not show
sufficiently high sensitivity to be used as a single antigen.
Therefore, rUreG in combination with other potential
diagnostic markers, such as rCagA, rUreB, and/or rVacA,
may be investigated as a cocktail diagnostic reagent for the
development of a robust test for H. pylori infection with
effective worldwide application. Future studies should also
be performed to evaluate the usefulness of rUreG in dis-
tinguishing the different clinical presentations of H. pylori
infection, i.e., acute symptoms (such as duodenal ulcer or
gastric cancer), chronic symptoms (such as dyspepsia), or
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would be the preferred method for an effective diagnostic
assay, however, further work to increase the purity of the
recombinant protein may be required to maintain its high
diagnostic specificity.
Conclusion
In this study, the full-length, open reading frame of the 25-
kDa UreG protein of H. pylori, a potential diagnostic
marker, was cloned into the TOPO-TA vector, and sub-
cloned into the pRSET expression vector. The recombinant
form of the UreG protein showed high reactivity with
H. pylori patients’ sera and no reactivity with most other
sera, as well as good immunogenicity in mice. Thus,
rUreG is a promising candidate for the diagnosis of
H. pylori infection, either singly, or in combination with
other diagnostic reagents.
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